The Future of Facial EMS, Smarter Delivery Over Raw Intensity
Medically reviewed by
4 independent reviewers
Andrew Conrad Barile, PT, DPT
Doctor of Physical Therapy (DPT) | Licensed Physical Therapist (PT) | CEO and Founder, Xtreem Pulse LLC
Read bio
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC, the engineering company behind PureLift. He earned his Doctorate in Physical Therapy from Daemen College and is a licensed physical therapist.
He brings over two decades of clinical and entrepreneurial experience across physical therapy, craniosacral therapy and medical device innovation, built on a working knowledge of human anatomy and muscle physiology.
For PureLift LAB he reviews how current is delivered across all ten levels, from sub-sensory nanocurrent and skin-level microcurrent to motor-level EMS, and how the Infuse pass fits into the same ten-minute routine.
Bertica M. Rubio, M.D.
Board-Certified Physician, Dartmouth Medical School | Medical Director, Antiaging Regenerative Medicine Clinic
Read bio
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Doctor of Medicine from Dartmouth Medical School and completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, she specialises in age management medicine, regenerative medicine, wound healing and growth factor therapies, and her practice integrates evidence-based medical science with advanced aesthetic treatment.
For PureLift LAB she reviews articles for medical accuracy across the whole dial, from the gentle nanocurrent and microcurrent settings through to muscle-level EMS and the Infuse pass.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist | Head and Neck Surgeon | Fellow, American College of Surgeons | Mount Sinai
Read bio
Daniel Grinberg, MD, FACS is a board-certified otolaryngologist and head and neck surgeon at ENT and Allergy Associates in West Nyack, New York. He earned his medical degree from Columbia University College of Physicians and Surgeons.
He completed his otolaryngology residency at New York University Medical Center, serves as Assistant Clinical Professor at Mount Sinai School of Medicine, and is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
For PureLift LAB he brings a wider clinical lens, connecting at-home facial stimulation from microcurrent to EMS to the anatomy underneath, with the same rigour we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology
Read bio
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital.
He trained at the University of Hamburg, was a Max Planck Society Fellow at the Max Planck Institute for Heart and Lung Research, and held senior consultant posts at the Charite Universitatsmedizin Berlin before his appointment as Chair in 2016.
One of Europe's leading authorities on arteriogenesis, with over 150 peer-reviewed publications and US and EU patents, he reviews for PureLift LAB how the evidence on electrical stimulation is read and where its limits lie.
Share
The next useful step in facial devices is not more power, since the category already passed the point where more output helps, it is better delivery of the power already there.
This article looks at where the category is actually heading, such as:
- Why the output race ran out of road
- What a moving signal is designed to solve
- The evidence gap the whole category still has
- What would actually count as progress
- Which claims to distrust when the next wave arrives
and many more!
By the end you will know what to look for in the next device you are sold.
Key Points:
Past the point where a facial muscle contracts, additional output adds discomfort rather than results, so raw power stopped being the useful variable.
The remaining problems are delivery problems, keeping a session consistent, keeping contact even, and keeping people using the device.
The whole category, ours included, lacks head-to-head consumer trials, and that is the honest state of the evidence.
Real progress would be product-specific trials and published measurement conditions, not more modes on a dial.
Distrust any new device sold on a bigger number, a longer mode list, or a stronger sensation.
Facial devices spent a decade competing on how much current they could deliver, and that competition has largely finished.
What comes next is more interesting and much less glamorous, because the remaining problems are not about power at all.
Why the output race ran out of road
A review of kilohertz-frequency stimulation describes three separate thresholds in everyone, the point you feel the current, the point the muscle moves, and the point it hurts (Ward 2009).
Once a device reliably crosses the second of those, the useful work is being done, and every additional milliamp moves the user toward the third.
So a device that goes higher than the one next to it is not better in any way that reaches your face, and the industry knows it, which is why headline numbers have started being replaced by mode counts.
Mode counts are the same problem in different packaging.
The problems that are actually left
The first is consistency within a session, because a muscle given the same fixed signal for ten minutes gets used to it, your nerves get used to it too, and the session fades even though the output has not changed.
The second is contact, since current arriving through patchy coverage concentrates at the surface, which both stings and wastes the session, and no amount of engineering inside the device fixes a dry serum layer.
The third is adherence, which is the largest of the three, because the research timeline runs to twelve weeks and a device in a drawer performs identically to no device at all.
None of those three is solved by a bigger number.
What a moving signal is designed to solve
PDM, the delivery architecture inside every PureLift, moves the signal across 361 frequency points between 1,370 and 1,730 Hz so it does not repeat, and frequency is the only thing it varies, since amplitude stays exactly where you set it.
Pooling 22 studies, researchers found that stimulation which keeps changing produced more evoked force with less fatigue than a fixed pattern (Cavalcante 2026), and a randomised crossover trial found that varying the frequency reduced how quickly people habituated to it (Avendano-Coy 2019).
Not every study agrees, and one found variable trains tired muscle as much as constant ones (Papaiordanidou 2014).
So the claim stays narrow: it is designed to reduce accommodation, and it cannot make accommodation impossible.
A narrow claim that survives scrutiny is worth more to a category than a broad one that does not.
The evidence gap nobody in this category has closed
The facial research that exists is category research. In the largest facial trial of its kind, 108 women used daily muscle stimulation for twelve weeks and ultrasound measured an 18.6 percent increase in cheek-muscle thickness, with a clear difference from the untreated group at six weeks (Kavanagh 2012), and a double-blind sham-controlled trial in adults over 65 found muscle thickness and bite force increased after six weeks (Chang 2020).
Every one of those studies used its own device and its own protocol, so none of them tells you what any particular consumer product does.
No randomised trial has compared PureLift against NuFACE, FOREO, FaceGym or anyone else, and no competitor has one either.
That is the honest state of the whole category, and a brand claiming otherwise is describing a study that does not exist.
What would actually count as progress
Product-specific trials, where a named device is tested rather than a category, would change the conversation more than any new mode.
Published measurement conditions, so that an output figure means something comparable between brands rather than being a number chosen for a page.
Better contact design, since the interface between device and skin is where most sessions are actually lost.
Routines built around what people will genuinely keep doing, because a shorter session completed four times a week beats a longer one completed twice.
Honest timelines, since the fastest way to lose a customer at week three is to have promised them something at week two.
Claims to distrust when the next wave arrives
A bigger maximum output, which we have just established stops mattering above the contraction threshold.
A longer list of modes, unless each one is explained in terms of what it physically does differently.
A stronger sensation, since a sharp feeling usually means current concentrating at the surface rather than reaching deeper.
An artificial intelligence claim with no description of what is being measured or adjusted.
Any device sold on clinical language with no clearance number you can look up.
Where we stand
All five PureLift models run nanocurrent at level 1, microcurrent at level 2, EMS from level 3 to 10, and Infuse as a second pass, and all five carry PDM.
Face at $499 and Pro at $699 reach up to 7 milliamps, Pro Edition at $799 reaches up to 7.7, and Pro Plus + at $899 and GLOW at $999 reach up to 9, all measured at 500 ohms and always written as up to.
The session is three minutes on each side of the face, about ten minutes including the Infuse pass.
GLOW alone adds light, red at 634 nm cleared for the treatment of wrinkles, blue at 465 nm cleared for mild-to-moderate inflammatory acne, and purple, which is red and blue running together.
Every model is cleared through the FDA 510(k) pathway, under records K190269 for Face, K230506 for Pro and Pro Edition, K221443 for Pro Plus + and K243587 for GLOW.
All five are made in Japan in an ISO 13485 facility.
By our own standard above, we have the same gap everyone else does, and closing it is the work rather than the marketing.
Anyone with a pacemaker or another implanted electronic device, anyone pregnant, and anyone with epilepsy or a seizure disorder should not use the device at all.
For how to read any brand's numbers, read the spec sheet guide, and for why turning it up is not the answer, read controlled power.
Model figures verified on 9 September 2026 against the PureLift LAB store and FDA records K190269, K230506, K221443 and K243587. Every model runs nanocurrent, microcurrent, EMS and Infuse; consumer copy always says up to.